721 related articles for article (PubMed ID: 37042255)
1. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.
Harrington J; Carnicelli AP; Hua K; Wallentin L; Patel MR; Hohnloser SH; Giugliano RP; Fox KAA; Hijazi Z; Lopes RD; Pokorney SD; Hong H; Granger CB
Circulation; 2023 Jun; 147(23):1748-1757. PubMed ID: 37042255
[TBL] [Abstract][Full Text] [Related]
2. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.
Carnicelli AP; Hong H; Connolly SJ; Eikelboom J; Giugliano RP; Morrow DA; Patel MR; Wallentin L; Alexander JH; Cecilia Bahit M; Benz AP; Bohula EA; Chao TF; Dyal L; Ezekowitz M; A A Fox K; Gencer B; Halperin JL; Hijazi Z; Hohnloser SH; Hua K; Hylek E; Toda Kato E; Kuder J; Lopes RD; Mahaffey KW; Oldgren J; Piccini JP; Ruff CT; Steffel J; Wojdyla D; Granger CB;
Circulation; 2022 Jan; 145(4):242-255. PubMed ID: 34985309
[TBL] [Abstract][Full Text] [Related]
3. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
[TBL] [Abstract][Full Text] [Related]
4. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Bohula EA; Giugliano RP; Ruff CT; Kuder JF; Murphy SA; Antman EM; Braunwald E
Circulation; 2016 Jul; 134(1):24-36. PubMed ID: 27358434
[TBL] [Abstract][Full Text] [Related]
5. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
Lawal OD; Aronow HD; Shobayo F; Hume AL; Taveira TH; Matson KL; Zhang Y; Wen X
Circulation; 2023 Mar; 147(10):782-794. PubMed ID: 36762560
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease.
Bhatia HS; Bailey J; Unlu O; Hoffman K; Kim RJ
Pacing Clin Electrophysiol; 2019 Nov; 42(11):1463-1470. PubMed ID: 31599969
[TBL] [Abstract][Full Text] [Related]
9. Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function.
Lee SR; Choi EK; Han KD; Jung JH; Cha MJ; Oh S; Lip GYH
Stroke; 2019 Jun; 50(6):1480-1489. PubMed ID: 31084339
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review and Meta-Analysis of Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation With Low Stroke Risk.
Fong KY; Chan YH; Yeo C; Lip GYH; Tan VH
Am J Cardiol; 2023 Oct; 204():366-376. PubMed ID: 37573616
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulation in Patients with Chronic Kidney Disease.
Elenjickal EJ; Travlos CK; Marques P; Mavrakanas TA
Am J Nephrol; 2024; 55(2):146-164. PubMed ID: 38035566
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis.
See LC; Lee HF; Chao TF; Li PR; Liu JR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; Lip GYH
Cardiovasc Drugs Ther; 2021 Oct; 35(5):975-986. PubMed ID: 33211254
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials.
Lin DS; Lo HY; Huang KC; Lin TT; Lee JK
J Am Heart Assoc; 2023 Dec; 12(23):e030380. PubMed ID: 38014696
[TBL] [Abstract][Full Text] [Related]
15. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
Hankey GJ; Stevens SR; Piccini JP; Lokhnygina Y; Mahaffey KW; Halperin JL; Patel MR; Breithardt G; Singer DE; Becker RC; Berkowitz SD; Paolini JF; Nessel CC; Hacke W; Fox KA; Califf RM;
Stroke; 2014 May; 45(5):1304-12. PubMed ID: 24743444
[TBL] [Abstract][Full Text] [Related]
16. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
[TBL] [Abstract][Full Text] [Related]
17. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.
Stanifer JW; Pokorney SD; Chertow GM; Hohnloser SH; Wojdyla DM; Garonzik S; Byon W; Hijazi Z; Lopes RD; Alexander JH; Wallentin L; Granger CB
Circulation; 2020 Apr; 141(17):1384-1392. PubMed ID: 32160801
[TBL] [Abstract][Full Text] [Related]
18. Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies.
Chan YH; Chan CY; Chen SW; Chao TF; Lip GYH
Europace; 2023 Oct; 25(10):. PubMed ID: 37738425
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).
Sherwood MW; Douketis JD; Patel MR; Piccini JP; Hellkamp AS; Lokhnygina Y; Spyropoulos AC; Hankey GJ; Singer DE; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Becker RC;
Circulation; 2014 May; 129(18):1850-9. PubMed ID: 24552831
[TBL] [Abstract][Full Text] [Related]
20. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
